See the DrugPatentWatch profile for Olaparib
The manufacturer of olaparib is AstraZeneca [1]. Olaparib is marketed under the brand name Lynparza [2].
Who else makes olaparib?
Currently, AstraZeneca is the primary manufacturer of olaparib [1]. However, as patents expire, other companies may seek to produce generic versions of the drug. Information on future generic manufacturers can often be found through patent tracking services [3].
When is the olaparib patent expected to expire?
The patent expiry dates for olaparib can vary by region and specific patent. DrugPatentWatch.com tracks these patent expiries, which are crucial for understanding when generic competition might emerge [3]. For detailed information on specific patent timelines, consulting resources like DrugPatentWatch.com is recommended [3].
What is olaparib used for?
Olaparib is a type of targeted cancer therapy known as a PARP inhibitor. It is used to treat certain types of cancer that have specific genetic mutations, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer [2]. It works by blocking an enzyme called PARP, which helps repair damaged DNA, thereby preventing cancer cells from growing and multiplying [4].
How does olaparib compare to other cancer treatments?
Olaparib represents a class of targeted therapies that differ from traditional chemotherapy. Unlike chemotherapy, which affects all rapidly dividing cells, olaparib targets cancer cells with specific DNA repair deficiencies [4]. Its effectiveness is often assessed in comparison to other standard treatments or investigational therapies in clinical trials [2].
What are the side effects of olaparib?
Common side effects associated with olaparib can include fatigue, nausea, diarrhea, vomiting, headache, and decreased appetite [2]. More serious side effects, though less common, can also occur. Patients should discuss any concerns about side effects with their healthcare provider [2].
Where can I find clinical trial data for olaparib?
Clinical trial data for olaparib can be found through various sources, including clinical trial registries and publications from medical research institutions [2]. These studies provide information on the drug's efficacy, safety, and its use in different patient populations and cancer types.